Human papillomavirus DNA testing for cervical cancer screening: practical aspects in developing countries.
Cervical cancer is the second most common cancer in women worldwide, and the most common cause of death from cancer in women in the developing world. Cervical cancer represents the only gynecologic cancer that can be prevented through regular screening. Although there are established screening programs in the Western world that have effectively reduced the burden of cervical cancer, these programs have relied on insensitive screening technologies that depend on the long preinvasive phase of cervical carcinogenesis. The developing world faces specific additional challenges in implementing a successful cervical cancer screening program. The association between cervical cancers and human papillomavirus (HPV) make testing for the presence of HPV DNA a valuable screening tool. This review focuses on practical aspects of the implementation and delivery of HPV testing as the primary cervical cancer screening strategy in the developing world, and attempts to offer some solutions to the real-world challenges faced in these regions.
Belinson
Suzanne E
SE
Preventive Oncology International, Inc., Cleveland Heights, Ohio 44118, USA. seb@poiinc.org
Belinson
Jerome L
JL
D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000453:epidemiology / Q000821:virology; D002584:Cervix Uteri / Q000821:virology; D004279:DNA, Viral / Q000302:isolation & purification*; D003906:Developing Countries; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D027383:Papillomaviridae / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000175:diagnosis*; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000821:virology; D014626:Vaginal Smears
D004279:DNA, Viral
Cancer. 1998 Nov 15;83(10):2150-6
9827719
Int J Gynecol Cancer. 2009 Jan;19(1):27-32
19258937
J Obstet Gynaecol. 2001 Nov;21(6):617-21
12521783
J Clin Microbiol. 2006 Apr;44(4):1310-7
16597856
Cochrane Database Syst Rev. 2010 Jun 16;(6):CD001318
20556751
Int J Cancer. 2010 Sep 1;127(5):1151-7
20039323
Obstet Gynecol. 1998 Nov;92(5):737-44
9794661
J Clin Virol. 2009 Jul;45 Suppl 1:S63-72
19651371
N Engl J Med. 2007 Oct 18;357(16):1579-88
17942871
Gynecol Oncol. 2001 Nov;83(2):439-44
11606114
Int J Cancer. 2006 Sep 1;119(5):1095-101
16586444
Clin Chem. 2008 Jan;54(1):86-92
17981923
Am J Epidemiol. 2009 Sep 15;170(6):708-16
19692327
Int J Cancer. 2008 May 15;122(10):2294-300
18240149
N Engl J Med. 2009 Apr 2;360(14):1385-94
19339719
Int J Cancer. 2006 Dec 1;119(11):2677-84
16991121
Lancet. 1987 May 30;1(8544):1247-9
2884378
N Engl J Med. 2007 Oct 18;357(16):1589-97
17942872
JAMA. 2003 Aug 13;290(6):781-9
12915431
Int J Gynecol Cancer. 2010 Apr;20(3):422-7
20375808
BMJ. 2008 Oct 13;337:a1754
18852164
Lancet. 2007 Aug 4;370(9585):398-406
17679017
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
Lancet Oncol. 2008 Oct;9(10):929-36
18805733
BMC Womens Health. 2010 Apr 01;10:11
20359354
J Clin Virol. 2009 Jul;45 Suppl 1:S93-7
19651375
Int J Gynecol Cancer. 2003 Nov-Dec;13(6):819-26
14675319
Br J Cancer. 2003 Jul 7;89(1):101-5
12838308
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1157-64
15894666
J Low Genit Tract Dis. 2003 Apr;7(2):107-16
17051055
J Pathol. 1999 Sep;189(1):12-9
10451482
Br J Cancer. 2003 Jan 13;88(1):63-73
12556961